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Kidney disease represents a serious global health problem. One of the main concerns is its late diagnosis, only feasible in a
progressed disease state. The lack of a clinical manifestation in the early stages and the fact that the commonly measured
parameters of renal function are markedly reduced only during advanced stages of the disease are the main cause. Changes at
the molecular level of the kidney tissue occur even before nitrogenous substances, such as creatinine and urea, start to
accumulate in the blood. Renal proximal tubules contain a large number of mitochondria and are critical for the energy-
demanding process of reabsorption of water and solutes. Mitochondria are the largest producers of oxygen radicals, which, in
turn, increase the susceptibility of kidneys to oxidative stress-induced damage. Free radicals and prooxidants produced during
acute or chronic kidney injury may further aggravate the course of the disease and play a role in the pathogenesis of subsequent
complications. Prevention might be the solution in CKD, but patients are often reluctant to undergo preventive examinations.
Noninvasive markers and the possibility to obtain samples at home might help to increase compliance. This review will provide
an overview of the possible uses of markers of oxidative status in noninvasive biofluids in patients with renal disease.
1. Introduction
Kidney disease is a worldwide health burden with a high
economic cost, which includes costs for physician visits,
emergency department visits, dialysis, drug cost, etc. [1–3].
It is estimated that annual medical costs for a patient with
chronic kidney disease are approximately 20 thousand USD
[4]. Kidney diseases are divided into two main categories,
acute kidney injury (AKI) and chronic kidney disease
(CKD). AKI has a fast progression and is characterized by a
loss of kidney function, which leads to the accumulation of
toxic end products of nitrogen metabolism and creatinine
in the blood of the patient. The estimated prevalence of
AKI is about 20–200 in a million people worldwide, while
around 2 million people worldwide die of AKI each year
[5]. CKD develops over a longer period of time and is charac-
terized by a gradual reduction in kidney function. CKD of all
stages is present in between 7 and 12% of patients in different
regions of the world [6]. The global prevalence of both AKI
and CKD is on the rise, partially because of the population
aging, but the observed rise can be associated with the
increase in hypertension and diabetes as well [6]. Moreover,
CKD is a serious independent risk factor for cardiovascular
disease, while AKI patients are at an increased risk of devel-
oping either de novo CKD or exacerbation of an underlying
CKD, leading to end-stage renal disease (ESRD) and the need
of renal replacement therapy [5, 6]. The search for screening
methods allowing earlier detection and more effective disease
monitoring of CKD is still ongoing. It is important to focus
the research on a better understanding of the risk factors of
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CKD progression and more effective and less costly therapies
of CKD in the later stages [7]. Renal tubule cells are rich in
mitochondria, because the reabsorption of solutes is energy
demanding. This makes kidney cells especially vulnerable to
oxidative stress and damage [8–10]. Free radicals and proox-
idants produced during the development of AKI and CKD
can aggravate the injury and could play a role in the onset
of severe complications in distant organs that are often
observed in AKI and CKD, such as cardiovascular diseases
and neurological complications [11, 12]. Several markers of
oxidative stress can be measured in the serum or tissue to
evaluate and monitor the disease state and progression [13].
Although serum represents a relatively stable environment
to measure systemic biomarkers, blood collection can be
stressful to patients. Hence, alternative biofluids are being
investigated as a potential biomarker source. Both saliva
and urine collection is inexpensive, easy to obtain in suffi-
cient volumes, fast, and without the risk of vessel injury or
infection [14]. The use of these alternative biofluids in clinical
practice would provide practitioners with an easier means of
disease monitoring.
2. Biomarkers of Oxidative Stress
Several comprehensive review articles regarding the physio-
logical and pathophysiological roles of reactive oxygen
species (ROS) and antioxidants in health and disease were
published recently [15–18]. The aim of this review is to focus
and designate current knowledge on oxidative stress bio-
markers obtained noninvasively that could be used in patients
with renal disease. ROS and reactive nitrogen species (RNS)
are involved in a number of signaling pathways regulating cell
growth and differentiation, mitogenic responses, extracellular
matrix production and breakdown, apoptosis, oxygen sens-
ing, and inflammation [19]. Besides their regulatory function,
ROS and RNS are also a part of the immune system defense
response against pathogenic microorganisms. On the other
hand, antioxidants inhibit the formation of free radicals and
prooxidants. A mechanism called antioxidant adaptation is
responsible for the signal formation and transport of the
appropriate antioxidant to the site of excessive free radical
and prooxidant production [20]. Antioxidant enzymes, for
example, glutathione peroxidase, glutathione S-transferase,
and phospholipid hydroperoxide glutathione peroxidase,
decompose lipid hydroperoxides to alcohols, and glutathione
peroxidase and catalase also reduce hydrogen peroxide to
nontoxic substances [21]. Hydrophilic or lipophilic endoge-
nous radical-scavenging antioxidants act via suppression of
redox chain initiation. Vitamin C, uric acid, bilirubin, albu-
min, and thiols are hydrophilic, while vitamin E and ubiquinol
are lipophilic radical-scavenging antioxidants. Proteolytic
enzymes and peptidases in cytosol and mitochondria can
recognize and degrade proteins damaged by oxidation and
prevent their accumulation, while glycosylases and nucleases
repair DNA damaged by oxidation. In addition, oxidative
stress is a state that occurs when free radicals and oxidants
increase to the point where they overpower the radical-
scavenging mechanisms of a cell [22]. However, this also
means that both excess and/or an insufficient amount or
activity of antioxidants may also cause oxidative stress
[23–25]. The result of such stress is damage to the macro-
molecules such as lipids, proteins, complex carbohydrates,
or nucleic acids also known as oxidative damage.
Direct analysis of free radicals in an in vivo system is
hampered by many complications, including their very short
lifespan and technical issues with their measurement. The
measurement of antioxidants is problematic, since a large
number of various antioxidants exist. This makes their deter-
mination time consuming and costly. Additionally, since a
variety of technical equipment is needed, one laboratory
would not be able to measure all antioxidants. Total antioxi-
dant capacity (TAC) and ferric reducing ability of plasma
(FRAP) measuring antioxidant power as a whole along with
an indirect way of measuring oxidative stress through by-
products and/or end products of oxidation reactions is more
feasible. Lipid peroxidation generates a wide range of prod-
ucts, which can be used as biomarkers [26, 27]. Reactive alde-
hydes, such as malondialdehyde (MDA), can easily react with
proteins to form advanced lipoxidation end products [28].
Carbonyl derivatives of amino acid residues lysine, proline,
threonine, and arginine can be used as markers of protein
oxidation. Advanced oxidation protein products (AOPP) are
widely established markers of protein oxidation [29]. Simi-
larly, advanced glycation end products (AGEs) are formed
by reaction of carbonyl substances such as carbohydrates
and proteins [30]. ROS and RNS can also damage nucleic
acids, generating pyrimidine and purine base adducts.
8-oxo-2′-deoxyguanosine is thought to be the most repre-
sentative product of oxidative modifications of DNA and
can correlate with the level of oxidative DNA damage in
the whole body [31]. Due to the single-strand nature of
RNA, its repair is not possible. The most extensively studied
RNA product modified by oxidation and a commonly
measured marker of oxidative RNA damage is 7,8-dihydro-
8-oxoguanosine [32]. It should be noted that because of
ubiquitous and nonspecific nature of oxidative stress, it is
always advantageous to measure a whole panel of biomarkers
instead of a single parameter, as this reduces a possibility of
relying on one false positive or negative result [26, 33].
3. Oxidative Stress in the Pathophysiology of
Acute Kidney Disease
Oxidative stress is considered an important player in the
pathophysiology of both, AKI and CKD. AKI is characterized
by an abrupt loss of kidney function (within a week) resulting
in an accumulation of toxic end products of nitrogen
metabolism and creatinine in the blood, decreased urine out-
put, or both. AKI can develop prerenally, as a consequence of
decreased renal blood flow, on a renal level, caused by damage
to the renal parenchyme, or postrenally, by the obstruction of
urine flow from the renal collecting system or ureters [34, 35].
On a cellular level, the pathophysiology of AKI is character-
ized by complex interactions between immune cells causing
inflammation and mediators with kidney cells [36]. The
following reparatory process leads to either the restoration
of kidney function or profibrotic phenotype that results in
chronic kidney disease.
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Hypoperfusion caused by decreased blood flow to the
kidneys is the most common cause of AKI [37]. Such prere-
nal AKI may or may not result in a cellular injury manifested
as ischemic acute tubular necrosis. The highly metabolically
active proximal tubular cells and medullary thick ascending
limb cells are the primary targets in such injury due to their
high oxygen demands [38]. Following injury, the epithelial
cells undergo structural changes or cell death, triggering
endothelial activation and the infiltration of cells releasing
inflammatory mediators [39]. Ischemia and reperfusion are
also activators of oxidative stress, with mitochondria being
the primary source of ROS in this setting [40]. During ische-
mic injury, ROS, such as the hydroxyl radical peroxynitrite
and hyperchlorous acid, are generated. At the same time,
antioxidant enzymes, such as superoxide dismutase (SOD),
catalase, and glutathione reductase, are depleted. This has
been shown in renal tissue after both renal ischemia and
nephrotoxicity [41–43]. Ischemic injury also upregulates
the expression of proinflammatory cytokines and recruits
phagocytes that also generate ROS. In turn, ROS influence
the vasoconstriction and renal vascular resistance [44, 45].
Sepsis-induced kidney injury is a result of both prere-
nal (hemodynamic changes, endothelial dysfunction) and
intrarenal (inflammatory infiltration and renal parenchyma
damage, intraglomerular thrombosis, and tubular obstruc-
tion) causes, but the exact cascade of events is not yet entirely
known [46]. ROS are involved in the development of sepsis-
induced kidney injury on multiple levels. Inflammation-
induced upregulation of inducible nitric oxide synthase leads
to production of excessive nitric oxide (NO), and that in turn
uncouples endothelial NO synthase generating highly reac-
tive superoxides by oxidation of oxygen [36]. In addition,
the excessive NO competes with SOD and reacts with
superoxide radicals creating peroxynitrite, which has a
direct damaging effect on tubular cells [47, 48]. Finally,
because the expression of inducible NO synthase is heteroge-
neous, the concentrations of NO vary, resulting in uneven
perfusion [36, 48].
Inflammatory cells are notoriously known to use ROS as
a part of their modus operandi. In septic AKI, dendritic cells
and neutrophils are the key players in promoting renal dis-
ease [49]. While dendritic cells contribute to oxidative stress
indirectly by recruiting and activating neutrophils, activated
neutrophils can undergo two different ROS-dependent
mechanisms to combat immediate threats. Phagocytosis
(threat engulfment and “oxidative burst” activation) and
NETosis (formation of neutrophil extracellular traps) require
the activation of NADPH oxidase 2 (NOX2) and the produc-
tion of superoxide. A recent study showed that blocking of
NOX2 and inducible NO synthase in neutrophils decreases
kidney injury in a mouse model of sepsis-induced AKI [49].
Oxidative stress plays an important role in the pathogen-
esis of rhabdomyolysis-induced myoglobinuric AKI. In rhab-
domyolysis, the porphyrin ring of myoglobin is catabolized
in tubules, releasing its iron content. The released iron then
participates in Fenton and Haber-Weiss reactions, where cat-
alytic amounts of iron are enough to produce ROS. Also, the
heme group in myoglobin itself can promote lipid peroxida-
tion reactions [50].
Drug-induced tubular necrosis is an acute, intrinsic renal
form of AKI. The pathophysiology includes direct toxic effect
of drugs on tubular cells [51]. A common form of nephro-
toxic AKI is induced by cisplatin, a chemotherapy drug used
to treat a number of cancers. Cisplatin invokes increased
ROS production after being activated into a highly reactive
form, reacts with thiol-containing molecules, such as gluta-
thione (GSH), and depletes them [52, 53]. A decrease in
cellular antioxidants can lead to the accumulation of
endogenous ROS that activates signaling pathways leading
to the death of renal tubular cells. Cisplatin may also
induce mitochondrial dysfunction, leading to an increase
in ROS production [54], and induce ROS formation in
the microsomes via cytochrome P450 enzymes [55]. Stud-
ies in critically ill patients and sepsis patients with AKI
showed that elevated circulating protein and lipid oxida-
tion products correlated with the proinflammatory and
prooxidative mediators and cytokines [56]. AKI and oxida-
tive stress hold a bidirectional relationship in critically ill
patients, as oxidative stress induced in AKI contributes
to further injury.
4. Oxidative Stress in the Pathophysiology of
Chronic Kidney Disease
CKD is characterized by a reduction of kidney structure and
function over a period of time, to a glomerular filtration rate
below 60ml/min/1.73m2 for more than 3 months, or an
albumin-creatinine ratio over 30mg of albumin for 1 g of
creatinine in urine. The common causes of CKD include
diabetes mellitus, hypertension, glomerulonephritis, or
polycystic kidney disease. Over the course of CKD, patients
progress through several stages [34, 57]. CKD generally has
a slow progression, which depends on the primary disease
as well as other influencing factors, such as diet, smoking,
or coexisting metabolic disease. The progression of CKD to
its advanced stages was shown to be associated with a signif-
icant increase in the generation of free radicals and other
prooxidants. Several studies showed that the plasma markers
of oxidative stress were elevated in CKD patients, indicating
increased systemic oxidative stress [58–60]. Various cellular
processes can serve as a source of oxidative stress in CKD
patients. The combination of oxidative stress, chronic
inflammation, and endothelial dysfunction is recognized as
a triad perpetuating the bidirectional vicious cycle between
CKD and systemic complications [61]. The development of
oxidative stress in CKD is thus entwined with the progression
of the disease, both as a cause and as a consequence of CKD
[62]. Impaired mitochondrial function and enhanced mito-
chondrial ROS have been proposed as one of the causes of
elevated oxidative stress in CKD. Impaired mitochondrial
function might also be the cause of the lower energy
metabolism displayed by many CKD patients [63]. A study
comparing conservative treatment and haemodialysis in
CKD patients found that the mitochondrial respiratory sys-
tem was dysregulated in CKD, and this dysregulation was
associated with enhanced oxidative stress [64]. In diabetic
kidney disease, mitochondrial overproduction of ROS is
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associated with mitochondrial dysfunction, which ultimately
leads to cellular damage and disease progression [63].
Animal studies on diabetic mice have shown enhanced mito-
chondrial ROS in the kidneys [65–67]. One study used a
GFP-based redox-sensitive biosensor specifically localized
in the mitochondrial matrix to prove that the enhanced oxi-
dative stress is generated specifically in the mitochondria of
diabetic mice [68]. Inflammatory processes are important
players in the development of CKD. Inflammation has been
linked to oxidative stress in CKD, although the precise nature
of this relationship is not yet clear. There is a correlation
between renal disease and markers of inflammation such as
high-sensitivity C-reactive protein, interleukin- (IL-) 6,
tumor necrosis factor-α, and fibrinogen. These molecules
may induce oxidative stress via several signaling pathways
[69–71]. For example, polymorphonuclear cell neutrophils
generate myeloperoxidase (MPO) and activate ROS excre-
tion. Serum MPO was found to be associated with markers
of inflammation in CKD patients [72]. Increased oxidative
stress may reversely worsen inflammation, setting up a
vicious circle perpetuated by the activation of a nuclear tran-
scription factor κB (NF-κB), which orchestrates immune cell
activation and recruitment. This way, inflammatory cyto-
kines associated with oxidative stress promote the damage
of renal tissues by inducing apoptosis, necrosis, and fibrosis
and may play an important role in the pathogenesis and pro-
gression of CKD [73]. Another source of oxidative stress in
CKD patients may be the presence of uraemic toxins. Urae-
mic toxins promote inflammation, as well as oxidative stress,
by priming polymorphonuclear cells, activating IL-1β and
IL-8 and the innate immune response. Uric acid (UA) pro-
duction during purine degradation through the activity of
xanthine oxidoreductase and subsequent superoxide forma-
tion promotes oxidative stress. Nevertheless, increasing evi-
dence suggests that UA itself functions as a powerful
antioxidant in vivo [74–77].
Dysregulated metabolic waste disposal in later stages of
CKD is also an important contributor to oxidative stress
induction. In ESRD, renal replacement therapy with mainte-
nance haemodialysis can aggravate oxidative stress in each
session, due to ROS excretion by phagocytes on the surface
of dialysis membranes. In addition, haemodialysis further
exhausts the antioxidant capacity of the body [78–80]. Oxi-
dative stress may contribute to endothelial dysfunction and
can also aggravate atherosclerosis and lead to the develop-
ment of cardiovascular disease or various malignancies in
ESRD patients [81–83]. Increased ROS production also
induces structural changes in β2-microglobulin, which are
associated with the incidence of amyloidosis due to inflam-
matory processes in CKD [84]. Other features associated
with oxidative stress in CKD include anaemia, hypertension,
kidney fibrosis, neurologic disorders, and accelerated aging
[85, 86] as summarized in Figure 1.
5. Monitoring Kidney Disease via
Measurement of Salivary/Urinary Markers of
Oxidative Stress
Markers of oxidative stress are usually measured in plasma or
serum, which are relatively stable environments for the eval-
uation of systemic biomarkers. However, acquisition of blood
might represent a significant stress to the patient. Thus, other
biofluids are being tested as alternatives to plasma. These bio-
fluids should be easier to collect, and patients should be able
to produce sufficient volumes [14]. The collection of saliva is
inexpensive, fast, and noninvasive. During the collection pro-
cess, the risk of vessel injury and infection is eliminated.
Older, less compliant patients and young children prefer
the collection of saliva. Urine could also be a promising alter-
native biofluid for the assessment of oxidative stress, as urine

















Figure 1: Causes and possible consequences of oxidative stress in acute and chronic kidney diseases. Increase in oxidative stress occurs as a
consequence of behavioral factors and physiological and pathophysiological processes in the human body (left panel). In turn, oxidative stress
contributes to the development of a variety of injuries (right panel), which may further promote oxidative stress and aggravate the initial
cause, creating a “vicious circle” between oxidative stress and tissue injury.
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with no effort, equipment, or trained staff. Urine samples can
also be obtained in extensive volumes, many times in one
day. In addition, some argue that urine could be a better envi-
ronment for the assessment of oxidative stress markers than
plasma, as its metal-containing organic and inorganic com-
pound content is lower. Due to the lower levels of ROS pro-
moters, urine is less prone to artificial increase of oxidative
stress markers during sample collection and storage [87].
Urine and saliva samples could also be collected at patients’
homes, because they can be stored and transported without
much effort. Although it is feasible to analyze a wide range
of biomarkers in urine or saliva, the use of these biofluids
in clinical practice is limited, due to a high intra- and interin-
dividual variability of the markers (Table 1) [88]. Up to date,
only a few clinical studies have been focused on salivary/-
urinary markers of oxidative stress in relation to kidney
diseases. They are summarized in Table 2.
5.1. Nitric Oxide. NO is involved in many normal physiolog-
ical processes, as well as in oxidative stress induction under
pathological circumstances. Studies confirmed that NO is
increased in saliva of CKD patients of moderate and predia-
lysis stage when compared to controls. On the other hand,
the concentration of NO is lower when compared to patients
with CKD on haemodialysis [89, 90]. Even more interesting,
the salivary concentrations of NO in ESRD patients on
haemodialysis decreased significantly after dialysis [90, 91].
Although it seems that NO is a suitable marker with rapid
salivary dynamics in CKD, it should be noted that all three
studies used well-defined patients with exclusion of smokers
and patients with periodontal diseases. Both smoking and
periodontal diseases alter oxidative stress parameters per se
and could possibly interfere with NO measurements. Before
widespread clinical utilization, these factors should be stud-
ied or at least considered. Moreover, to our knowledge, there
are no studies for NO in patients with AKI.
5.2. Uric Acid. UA is an important free radical scavenger in
saliva and represents about 70-80% of salivary scavenging
capacity [92]. Clinical studies evaluating salivary UA and
CKD validated UA as a suitable biomarker for monitoring
the CKD progression and/or efficacy of dialysis [93, 94]. This
was confirmed not only in adults but also in children. Bibi
et al. observed a 22% decrease in salivary UA concentration
after dialysis [94], while Ben-Zvi et al. showed approximately
65% decrease [93]. Nevertheless, the latter study included
patients with ESRD and diabetes. Maciejczyk et al. showed
UA to be increased 8-fold in children with CKD when com-
pared to the control group without CKD [95]. Additionally,
this was so far the only study calculating the sensitivity and
specificity, being more than 60% for both.
It is worth mentioning that either unstimulated saliva
obtained by passive drooling or saliva collected using the
Salivette system is appropriate and does not affect UA con-
centrations [92]. Uncorrected or nonnormalized values of
UA correlated well with serum concentrations, at least in
healthy volunteers. Blood contamination and oral health sta-
tus were not associated with significant change in salivary UA
concentrations [96]. Age, ethnicity, and daytime also did not
affect UA levels in saliva. However, males had about 40%
higher concentration of UA in saliva than females. Similarly,
higher UA concentration was positively and significantly
associated with body mass index. Nevertheless, if the sample
is properly collected, UA in saliva has great potential to be
used for routine evaluation.
5.3. Other Markers of Antioxidant Status. Other, more com-
plex antioxidant status markers or high-molecular antioxi-
dants can be measured in saliva as well. When compared to
UA, their relation to kidney disease is more complicated.
For example, a slight decrease in TAC and SOD following
dialysis in patients without diabetes was confirmed. How-
ever, in patients with diabetes, the increase of TAC and
SOD was found to be insignificant [93]. Also, significantly
higher activity of peroxidase and SOD in stimulated saliva,
along with the lower concentration of GSH in both stimu-
lated and unstimulated saliva of CKD children, was
observed in comparison to the control group [95]. TAC,
total oxidant index, and oxidative stress index were signif-
icantly higher only when measured in stimulated saliva,
Table 1: Main advantages and disadvantages of blood, urine, and saliva collection and of measuring markers of oxidative stress and
antioxidant status in these body fluids.
Blood collection Urine collection Saliva collection
Advantages
Stable environment
Collectible in sufficient amounts
Established referenced values
Noninvasive, without stress
Easy to collect at home
Easy to collect in sufficient amounts
Inexpensive and fast collection
No risk of infection
Low organic/inorganic metal amount:
no artificial increase of oxidative stress
Noninvasive, without stress
Easy to collect at home
Inexpensive and fast collection
No risk of infection
Low organic/inorganic metal amount:
no artificial increase of oxidative stress
Disadvantages
Invasive and stressful
Risk of vessel injury and infection
Requires equipment
Requires a trained staff
Time consuming
Organic/inorganic metals present:
artificial increase of oxidative stress
Not established (missing reference
values)
High variability (hydration status,
gender, age, weight, local changes, etc.)
Not established (missing reference values)
High variability (flow rate, hydration status,
gender, age, weight, blood contamination,
local changes, etc.)











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6 Oxidative Medicine and Cellular Longevity
while oxidative damage products (AGEs, AOPP, and MDA)
were significantly higher in CKD children compared to con-
trols regardless the type of samples [95]. This study has dem-
onstrated that the saliva collection protocol might be of
importance when measuring markers of oxidative stress in
relation to kidney disease. Previously, our group also showed
that using different collection tubes, daytime sampling, or
periodontal status could interfere with downstreammeasure-
ments of markers of oxidative stress as well as antioxidant
status [97–99].
Recently published study by Maciejczyk et al. [100]
showed very promising results of FRAP measurement in
saliva and urine of pediatric CKD patients. Based on mea-
sured FRAP concentrations in saliva, they were able not only
to discriminate control patients and patients with CKD but
also to distinguish early stage CKD patients with more severe
stage CKD patients. Moreover, stimulated salivary FRAP
significantly correlated with both serum creatinine and
urea [100].
It is possible to analyze the individual antioxidants; how-
ever, due to the high number of low- and high-molecular
weight antioxidantmolecules present in saliva, the assessment
of total antioxidant capacity seems to be more appropriate. It
appears that TAC sufficiently reflects the disturbances in
antioxidant defense of CKD patients with different stages
of disease [100]; however, further clinical/methodological
studies are needed to confirm this.
5.4. AOPP, AGEs, and MDA. There are not many studies
measuring salivary markers of oxidative damage to lipids
(MDA), proteins (AOPP), and aldehyde (AGEs) molecules
that would be in relation to kidney disease. Nevertheless, all
three biomarkers seem to be increased in patients with
CKD, at least in children [95]. AOPP have showed the high-
est diagnostic value for CKD in both stimulated and nonsti-
mulated saliva with the best sensitivity/specificity profile
[95]. However, in adults, studies evaluating these markers
in saliva of CKD patients are missing.
Markers of oxidative status in urine were studied in
patients undergoing liver transplantation, to assess their abil-
ity to predict early AKI [101]. Despite the same baseline
levels of markers in both groups, significantly higher concen-
trations of MDA, 6-keto-prostaglandin Flα, H2O2, and 8-iso-
prostaglandin F2α and lower concentration of SOD were
observed in the group of patients that developed AKI. Dif-
ferences were present both 2 hours after graft reperfusion
and 24 hours after transplantation [101]. Possible predic-
tive and diagnostic values of urinary MDA as a marker for
AKI in critically sick full-term newborns were also suggested
[102]. To our best knowledge, no other clinical studies
were published.
6. Conclusion
Oxidative stress damages renal tissue and promotes inflam-
mation leading to further tissue injury with accumulation
of impaired biomacromolecules. These can be measured also
in saliva and urine which are easily collectible. Especially
promising are the markers UA, FRAP, and AOPP. The
current literature agrees that salivary concentrations of these
biomarkers correlate well with progressed stage renal disease.
Within the stage of renal disease, the salivary dynamics also
shadows the plasma concentrations. Nevertheless, high vari-
ability (and low specificity) of these markers in saliva or urine
has prevented their usage in routine clinical practice. Sensi-
tivity and specificity studies with determination of cut-off
values are missing, apart from those in children. Future
research should yield reference values that could be further
developed in standardized tests for home-based monitoring
of renal disease progression in patients.
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